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ABSTRACT
Background: To assess the prognostic and predictive factors of time to treatment 
failure (TTF) and overall survival (OS), respectively, in patients with metachronous 
metastatic renal cell carcinoma (mRCC) who were treated with targeted agents.
Materials and Methods: We retrospectively reviewed metachronous mRCC 
patients, defined as individuals diagnosed with metastatic disease >3 months after 
initial nephrectomy, treated at an institute since 2005. Cox proportional hazard 
regression analysis was performed to discover the most determinant variables 
associated with TTF and OS.
Results: Sarcomatoid features, absence of metastasectomy, multiple site 
metastasis, time to metastasis <1.5 year, and increased corrected calcium were 
independent prognostic factors of OS. The low risk group (0–1 risk factors) did not 
reach the median OS, whereas the OS for the intermediate (2 risk factors) and high 
risk groups (3–5 risk factors) were 58.6 and 23.6 months, respectively (p<0.001). 
When a death event was considered the dependent factor, the area under the 
receiver operating characteristic curve was significantly higher than in the existing 
International mRCC Database Consortium (IMDC; p=0.010) and Memorial Sloan 
Kettering Cancer Center (MSKCC; p=0.010) risk criteria models.
Conclusion: Initial tumor size or T stage did not affect TTF or OS. Patients who 
could not undergo metastasectomy and rapidly developed multiple metastases with 
higher corrected calcium and initial tumors with sarcomatoid features were less likely 
to benefit from targeted therapy; thus, the new agents under development or clinical 
trials could be more helpful than the use of standard targeted agents.
INTRODUCTION
The surgical resection of localized renal cell 
carcinoma (RCC) results in a 5-year survival of 
approximately 90% [1]. However, widespread metastatic 
RCC (mRCC) develops in 30% to 40% of patients after 
the initial resection [2]. Further, there is a 7% chance 
of metachronous metastatic disease up to 5 years after 
nephrectomy and a 16% chance at 10 years [3]. Due to 
the high incidence of metastasis, the management of 
mRCC has been revolutionized by therapeutic targeting 
of molecular pathways, which results in improved tumor 
response and prolonged survival [1].
Although the use of targeted agents has dramatically 
improved the prognosis of mRCC patients, complete 
remission rates remain poor and resistance to targeted 
therapies is high [4-6]. Consequently, several other 
treatment modalities including surgical resection 
(metastasectomy), radiotherapy, and classical immune 
therapy are still used to extend overall survival (OS) 
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rates [7, 8]. Furthermore, we are currently awaiting the 
approval and availability of the next generation of immune 
checkpoint inhibitors, which are currently under clinical 
trials [9-11]. Hence, defining poor responders or those with 
increased resistance to targeted agents will significantly 
impact treatment planning outcomes.
Metastatic cancer is generally divided into 
synchronous and metachronous categories by the period 
between primary cancer treatment and the occurrence 
of metastasis, respectively. In the era of immune-based 
therapies, these two mRCC groups were investigated 
extensively and compared for inherently different 
characteristics, which revealed better survival rates in the 
metachronous metastatic group [12]. However, compared 
to synchronous mRCC, studies focused on the impact of 
targeted therapy on the prognosis and clinical outcomes of 
metachronous mRCC are limited. Accordingly, no specific 
prognostic model for metachronous mRCC has been 
introduced, whereas several prognostic risk groupings 
for whole mRCC have been demonstrated, including 
the Memorial Sloan–Kettering Cancer Center (MSKCC) 
criteria, the International mRCC Database Consortium 
(IMDC) risk criteria, and the UCLA Integrated Staging 
System [1, 13, 14].
Herein, we focused on the prognostic and predictive 
factors of time to treatment failure (TTF) and OS, 
respectively, as clinical parameters that are critical to 
targeted therapies in patients with metachronous mRCCs.
RESULTS
In this study, retrospective reviews of 101 patients with 
metachronous RCC were conducted (Table 1). The mean age 
at diagnosis was 58.4±11.4 years and 73.3% were male. The 
histologic characteristics of the initial tumor included clear 
cell types (90.1%) and 68.3% were Fuhrman grade 3–4. 
Approximately, 10% exhibited sarcomatoid features and 
histologic necrosis. Patients with tumors with sarcomatoid 
features were placed in the Fuhrman grade 3–4 group. Half 
of the patients were stage T3, followed by T1 (29.7%) and 
T2 (19.8%). Single site metastasis was observed in 32.7% 
of the patients, with the lungs being the most common first 
metastasis site, followed by retroperitoneal space, bone, 
lymph node, and liver. Among 101 patients, death event 
occurred in 45 patients (44.6%). The median follow-up 
duration and time to metastasis were 37.0 [18.3, 59.4] and 
13.2 [6.1, 34.1] months, respectively. The median TTF and 
OS were 19.2 [9.3, 40.2] and 23.6 [10.7. 38.5] months, 
respectively. Metastasectomy was performed in 40 patients 
(39.6%), and the most frequently performed surgery was 
lung wedge resection (35%, 14/40) followed by metastatic 
bone resection (22.5%, 9/40). Metastasectomy was both 
performed in single site metastasis and multiple site 
metastasis condition. Sunitinib was the most common first-
line targeted agent (46.5%), followed by sorafenib (26.7%) 
and pazopanib (15.8%); however, no differences in OS or 
TTF were observed between the first line agents (p=0.706 
and 0.872, respectively). The patients that underwent a 
metastasectomy received targeted therapy treatment for 
a median period of 16.3 [6.5, 35.6] months prior to the 
metastasectomy, and the treatments were resumed as an 
adjuvant setting following a mean period of 2.1 [0.5, 3.8] 
months after the metastasectomy.
Predictive factors for TTF were analyzed by Cox 
regression (Table 2). Sarcomatoid features [hazard ratio 
(HR), 4.208; p=0.001], higher Fuhrman grade (3–4; HR, 
2.435; p=0.013), single metastatic site (HR, 0.455; p=0.030), 
and time to metastasis < 1.5 years (HR, 2.267; p=0.006) 
showed a significant impact on TTF (Table 2 and Figure 1) 
following the multivariate analyses. Using four independent 
factors, three risk groups were generated: low (risk factor=0; 
N=16, 16.3%), intermediate (risk factor=1; N=40, 40.8%) 
and high-risk (risk factor ≥2; N=42, 42.9%). A survival graph 
of each risk group was generated (Figure 2), which indicated 
significantly different TTF in the three risk groups (median 
TTF for low, intermediate, and high-risk groups: 67.6 vs 31.7 
vs 12.5 months, respectively; p=0.002)
Significant OS prediction factors were also analyzed 
by Cox regression (Table 3). Following multivariate analyses, 
sarcomatoid features (HR, 4.714; p=0.003), metastasectomy 
(HR, 0.437; p=0.045), single metastasis site (HR, 0.194; 
p=0.011), time to metastasis <1.5 years (HR, 3.053; p=0.011), 
and higher corrected calcium (for increase at every 1mg/dl) 
(HR, 5.607; p=0.001) were independent factors that affected 
OS (Figure 3). Using five independent factors, three risk 
groups were generated: low (risk factor=0–1), intermediate 
(risk factor=2), and high risk (risk factor=3–5). A survival 
graph of each risk group was generated (Figure 4), which 
demonstrated significant differences in OS between the 
groups (median OS in the low group was not reached, 
whereas OS for the intermediate and high risk groups were 
58.6 and 23.6 months, respectively; p<0.001).
The predictive discrimination of the C-indexes 
calculated for our model and the IMDC and MSKCC 
models were compared. The Harrell’s C-index value of 
our model was 0.745 (95% CI = 0.671, 0.815), which was 
greater than the IMDC C-index value of 0.659 (95% CI 
= 0.568, 0.739) and the MSKCC C-index value of 0.680 
(95% CI = 0.593, 0.755). The difference between the 
Harrell’s C-index of our model and the IMDC model was 
0.087 (95% CI = 0.004, 0.172), whereas the difference 
between our model and the MSKCC model was 0.066 
(95% CI = -0.017, 0.157). The AUC calculated by 
integrating over time was generally higher in our model 
compared to the IMDC and MSKCC models. When the 
death event served as the dependent factor, the area under 
the ROC curve (AUC) was significantly higher in our 
model compared to the other two models. The AUCs for 
our model and the IMDC model were 0.805 and 0.656, 
respectively (ours vs. IDMS, p=0.010), and the AUC 
for the MSKCC model was 0.659 (ours vs. MSKCC, 
p=0.010).
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Table 1: Baseline characteristics
Number of patients enrolled 101
Age at diagnosis of RCC, mean±SD (years) 58.4±11.4
Follow-up period after recurrence, median [IQR] (months) 37.0 [18.3, 59.4]
Gender, n (%)
 Male 74 (73.3)
 Female 27 (26.7)
Histology, n (%)
 Clear cell 91 (90.1)
 Non-clear cell 10 (9.9)
Fuhrman grade, n (%)
 G1 3 (3.0)
 G2 26 (25.7)
 G3 56 (55.4)
 G4 13 (12.9)
 Undefined 3 (3.0)
Sarcomatoid features, n (%) 10 (9.9)
Histological Necrosis, n (%) 9 (8.9)
Lymphovascular invasion, n (%) 23 (22.8)
Tumor stage
 pT1 30 (29.7)
 pT2 20 (19.8)
 pT3 51 (50.5)
Solitary site metastasis, n (%) 33 (32.7)
First site of metastasis, n (%)
 Retroperitoneal space 16 (15.8)
 Lung 41 (40.6)
 Liver 4 (4.0)
 Bone 12 (11.9)
 Brain 1 (1.0)
 Lymph node 5 (5.0)
 Others 22 (21.8)
Metastasectomy, n (%) 40 (39.6)
Time to metastasis from nephrectomy, median [IQR] 
(months)
13.2 [6.1, 34.1]
Time to initial treatment failure, median [IQR] (months) 19.2 [9.3, 40.2]
Time to death from metastasis, median [IQR] (months) 23.6 [10.7. 38.5]
Time to death from nephrectomy median [IQR] (months) 36.5 [19.2, 64.2]
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Univariate and multivariate logistic regression 
analysis was performed to sort the poor responders and 
those relatively resistant to targeted agents (Supplementary 
Table 1). The median duration of TKI treatment was 9.7 
months (0.8–72.7). Within this period, the poor responder 
patients exhibited shorter OS than the good responders 
(median survival: not reached vs 24 months, p<0.001). 
Following univariate analyses, sarcomatoid features, 
Table 2: Association of various factors with time to treatment failure in Cox proportional hazard regression analysis
Univariate analysis Multivariate analysis
Variables (n) HR 95% CI P 
value
HR 95% CI P value
Age: ≥60 years vs <60 years 
(53 vs 48)
1.157 0.711–1.884 0.558
Sex: males vs females (74 vs 
27)
0.815 0.461–1.442 0.482
Size ≥4cm (87 vs 14) 1.329 0.632–1.329 0.453
T stage 0.896
 pT1 (reference) (30)
 pT2 (20) 0.976 0.552–1.728 0.935
 pT3 (51) 1.135 0.612–2.105 0.687
Histological type: clear cell vs 
others (91 vs 10)
0.904 0.388–2.105 0.815
Sarcomatoid change (10) 2.745 1.340–5.623 0.006 4.208 1.736–10.196 0.001
Histologic necrosis (9) 1.157 0.528–2.537 0.716
Fuhrman grade: Grade 3-4 vs 
1-2 (69 vs 29)
2.554 1.383–4.716 0.003 2.435 1.203–4.928 0.013
Metastasectomy (40) 0.499 0.279–0.892 0.019 0.575 0.294–1.123 0.105
Metastatic sites: single vs 
multiple (33 vs 68)
0.482 0.271–0.858 0.013 0.455 0.223–0.928 0.030
Time to metastasis: <1.5yr vs 
≥1.5yr (54 vs 47)
2.060 1.257–3.376 0.004 2.267 1.266–4.060 0.006
First metastasis: 
Retroperitoneal space (16)
1.133 0.576–2.227 0.717
First metastasis: Lung (41) 0.830 0.508–1.354 0.455
First metastasis: Liver (4) 1.929 0.697–5.343 0.206
First metastasis: Bone (12) 1.124 0.556–2.273 0.745
First metastasis: Lymph node 
(5)
1.065 0.333–3.405 0.915
ASA: 3–4 vs 1–2 (26 vs 65) 0.907 0.503–1.637 0.746
Hemoglobin (g/dL) 0.886 0.768–1.023 0.099
LDH (IU/L) 1.005 0.996–1.015 0.258
Corrected calcium (mg/dL) 2.468 1.164–5.231 0.018 1.969 0.946-4.099 0.070
eGFR (CKD-EPI) (ml/
min/1.73m2)
0.992 0.975–1.008 0.319
HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiologists; LDH, lactate dehydrogenase; 
eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
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time to metastasis <1.5 years, lower hemoglobin, and 
higher corrected calcium levels were predictive values 
of poor responders, whereas single metastasis site and 
first metastasis in the lung were predictive of good 
responders. The multivariate analyses demonstrated 
that only sarcomatoid features and single site metastasis 
independently predicted poor and good responders, 
respectively [Odds ratio (OR), 8.355; p=0.034 and OR, 
0.218; p=0.016, respectively; Supplementary Figure 1].
A sub-analysis was performed using Cox 
regression to predict OS in patients who received first-
line TKI followed by a second-line mTOR inhibitor 
(Table 4). Total 32 patients were included in this 
group. 30 patients (93.8%) received everolimus, while 
remaining 2 patients (6.2%) received temsirolimus as 
second-line mTOR inhibitor. OS was defined as the time 
between the start of the second-line mTOR inhibitor to 
the date of death. The multivariate analysis revealed 
Figure 1: Kaplan-Meier plots of time to treatment failure by four risk factors (A) Fuhrman grade 3–4, (B) time to metastasis 
<1. 5 years, (C) multiple site metastasis, (D) sarcomatoid features.
Figure 2: Distribution (A) and Kaplan-Meier plots (B) of time to treatment failure of three risk groups: low (risk factor=0), 
intermediate (risk factor=1), and high (risk factor ≥2). 
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that sarcomatoid features (HR, 31.331; p=0.002) 
and first metastasis to bone (HR, 10.261; p=0.013) 
significantly influenced OS, whereas the duration of 
first-line TKI treatment was not associated with OS in 
the subjects (Figure 5).
DISCUSSION
Therapeutic options for mRCC have changed in 
recent years owing to the availability of targeted therapies 
[15], which have more than doubled the median OS for 
Table 3: Association of various factors with overall survival in Cox proportional hazard regression analysis
Univariate analysis Multivariate analysis
Variables (n) HR 95% CI P value HR 95% CI P value
Age: ≥60 years vs <60 years (53 
vs 48)
1.199 0.666–2.161 0.545
Sex: males vs females (74 vs 27) 0.732 0.389–1.377 0.333
Size ≥4 cm (87 vs 14) 1.653 0.591–4.620 0.338
T stage 0.871
 pT1 (reference) (30)
 pT2 (20) 0.821 0.350–1.928 0.651
 pT3 (51) 0.999 0.505–1.975 0.998
Histological type: clear cell vs 
others (91 vs 10)
0.734 0.260–2.072 0.559
Sarcomatoid change (10) 2.865 1.267–6.480 0.011 4.714 1.711–12.987 0.003
Histologic necrosis (9) 1.714 0.724–4.059 0.220
Fuhrman grade: Grade 3–4 vs 
1–2 (69 vs 29)
1.999 0.988–4.044 0.054
Metastasectomy (40) 0.484 0.253–0.925 0.028 0.437 0.194–0.983 0.045
Metastatic sites: single vs 
multiple (33 vs 68)
0.300 0.127–0.709 0.006 0.194 0.055–0.684 0.011
Time to metastasis: <1.5yr vs 
>1.5yr (54 vs 47)
3.313 1.675–6.553 0.001 3.053 1.291–7.221 0.011
First metastasis: Retroperitoneal 
space (16)
2.209 1.115–4.379 0.023 0.960 0.350–2.635 0.938
First metastasis: Lung (41) 0.345 0.170–0.698 0.003 0.830 0.345–1.998 0.677
First metastasis: Liver (4) 2.013 0.621–6.524 0.244
First metastasis: Bone (12) 1.475 0.686–3.171 0.319
First metastasis: Lymph node (5) 0.335 0.046–2.440 0.280
ASA: 3–4 vs 1–2 (26 vs 65) 0.975 0.460–2.068 0.948
Hemoglobin (g/dL) 0.798 0.677–0.940 0.007 0.958 0.786–1.168 0.673
LDH (IU/L) 1.004 0.994–1.015 0.420
Corrected calcium (mg/dL) 6.433 2.499–16.562 <0.001 5.607 2.116–14.852 0.001
eGFR (CKD-EPI) (ml/
min/1.73m2)
0.987 0.967–1.007 0.201
HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiologists; LDH, lactate dehydrogenase; 
eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration.
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Figure 3: Kaplan-Meier plots of overall survival by five risk factors (A) sarcomatoid features, (B) absence of metastasectomy, 
(C) multiple site metastasis, (D) time to metastasis < 1. 5 years, (E) higher corrected calcium levels.
Figure 4: Distribution (A) and Kaplan-Meier plots (B) of overall survival of three risk groups: low (risk factor=0–1), 
intermediate (risk factor=2), and high (risk factor≥3). 
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most mRCC patients [16]. Additionally, through lengthy 
and large cohort studies of various targeted agents, a variety 
of therapeutic agents with similar outcomes regarding OS 
and progression-free survival have been established [17].
We aimed to clarify the prognostic factors associated 
with metachronous mRCC in an attempt to prolong 
survival outcomes. Our study demonstrates interesting 
results regarding TTF and OS. Once the initial tumor was 
Table 4: Association of various factors with overall survival in patients that received first-line TKI and second-line 
mTOR inhibitor using Cox proportional hazard regression analysis (n=32)
Univariate analysis Multivariate analysis
Variables (n) HR 95% CI P value HR 95% CI P value
Age: ≥60 years vs <60 
years (17 vs 15)
1.903 0.633–5.723 0.252
Sex: males vs females (26 
vs 6)
0.495 0.152–1.615 0.244
Size ≥4cm (27 vs 5) 0.688 0.189–2.510 0.571
T stage 0.977
 pT1 (reference) (10)
 pT2 (2) 0.00 0.00–0.00 0.990
 pT3 (20) 1.128 0.374–3.407 0.830
Sarcomatoid change (2) 16.596 2.30–119.773 0.005 31.331 3.509–279.773 0.002
Histologic necrosis (3) 0.871 0.113–6.722 0.895
Fuhrman’s grade: Grade 
3–4 vs 1–2 (23 vs 9)
1.666 0.448–6.191 0.446
Metastasectomy (13) 0.576 0.180–1.844 0.353
Metastatic sites: solitary vs 
multiple (8 vs 24)
0.370 0.079–1.732 0.207
Time to metastasis: <1.5yr 
vs >1.5yr (21 vs 11)
2.231 0.611–8.143 0.225
First metastasis: 
Retroperitoneal space (3)
1.577 0.335–7.428 0.564
First metastasis: Lung (16) 0.318 0.099–1.021 0.054
First metastasis: Liver (3) 2.820 0.581–13.686 0.198
First metastasis: Bone (4) 5.443 1.024–28.924 0.047 10.261 1.649–63.850 0.013
First metastasis: Lymph 
node (2)
0.680 0.087–5.295 0.712
ASA: 3–4 vs 1–2 (4 vs 23) 0.485 0.062–3.767 0.489
Initial TKI duration 0.998 0.995–1.000 0.073
Hemoglobin (g/dL) 0.839 0.612–1.152 0.278
LDH (IU/L) 0.931 0.748–1.160 0.525
Corrected calcium (mg/dL) 3.720 0.880–15.732 0.074
eGFR (CKD-EPI) (ml/
min/1.73m2)
1.014 0.987–1.043 0.310
HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiologists; TKI, tyrosine kinase inhibitor; 
LDH, lactate dehydrogenase; eGFR, estimated glomerular filtration rate; CKD-EPI, Chronic Kidney Disease Epidemiology 
Collaboration.
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removed and residual tumor was absent, initial tumor size 
and T stage did not affect the prognosis in metachronous 
mRCC. Two prior studies have shown that size does not 
affect the prognosis of metachronous mRCC in small renal 
masses <4 cm [3, 18]. Nonetheless, size was a significant 
variable in the CORONA/SATURN-Project; however, the 
study primarily included patients treated with immune-
based therapies from 1992–2010 [19]. As well, the 
CORONA/SATURN-Project results suggest that initial 
T stage is a significant factor for OS [19]. It has been 
established that higher T stage demonstrates worse OS in 
synchronous mRCC [20]. In the current study, sarcomatoid 
features demonstrated the highest HR in metachronous 
mRCC and affected both TTF and OS, which was in 
accord with previous studies [21]. Further, Fuhrman grade, 
a well-known prognostic factor for both TTF and OS in 
synchronous mRCC [22], independently affected TTF and 
exhibited borderline significance (p=0.054) with regards 
to OS. We additionally applied WHO/ISUP grading 
system and WHO/ISUP grade also significantly affected 
TTF (p=0.013), while having borderline significance at 
OS (p=0.065). Finally, the first metastasis site was not 
clinically relevant, but the number of metastatic sites was 
a significant factor.
No guidelines for managing patients with refractory 
mRCC or that are resistant to targeted agents have been 
establishedA 5-year survival rate of 30%–45% has been 
reported in patients with mRCC after metastasectomy 
and the complete resection of all metastases has been 
associated with a 2-fold decrease in the risk of death [23]. 
Further, several researchers have stressed the integration 
of medical therapy and surgical resection. Alt et al. insisted 
that the optimal management of patients with mRCC 
was a combination strategy [23]. Similarly, Santini et al. 
demonstrated that multimodal treatment could be a valid 
approach to overcoming tumor heterogeneity involved in 
TKI resistance [4]. Additionally, Karam et al. analyzed 
the clinical significance of metastasectomy after targeted 
therapy and concluded that approximately 50% had no 
recurrence at a median of 43 weeks after combining both 
modalities [7].
Nonetheless, more accurate and concrete 
recommendations are needed regarding metastasectomy 
and the implication of each metastasis site. For example, 
Alt et al. indicated that metastasectomy is only effective 
when a complete resection is performed [23]. Regarding 
the site of metastasis, a pulmonary metastasectomy is 
beneficial when it involves metachronous metastasis with a 
long disease-free interval and a relatively small metastasis 
burden [12]. Dabestani et al. reported that with the 
exception of brain and bone metastases, metastasectomy 
remains the most appropriate local treatment for most sites 
[24]. However, metastasectomy for other sites are still 
controversial.
Regarding the time to metastasis factor, Poel et al. 
showed that patients with an interval <2 years between 
primary tumor and metastasis have significantly shorter 
disease-specific survival intervals compared to those 
with intervals >2 years [25]. According to Webber et al., 
whose study included all mRCC with or without prior 
nephrectomy, the only baseline variable consistently 
related to OS, TTF, and response to first-line anti-VEGF 
TKI therapy was time from diagnosis to treatment >12 
months. Brookman et al. reported that greater than 13,000 
patients with initially localized RCC had metachronous 
metastasis [19]. In this large study, time to metastasis 
<12 months, initial tumor size, and stage were prognostic 
factors, which was not in accord with our results. 
However, the study included heterogeneous treatments 
involving both immunotherapy and TKI, and did not 
Figure 5: Kaplan-Meier plots of overall survival following initiation of a second line mTOR inhibitor by two risk factors (A) 
sarcomatoid features and (B) first site of metastasis to bone. 
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consider metastasectomy. In our study, metastasectomy 
was performed in 40 patients (39.6%) who showed 
prolonged OS. Metastasectomy could be one of the 
options for patients who demonstrate short OS despite TKI 
treatment. Regarding clinical efficacy of metastasectomy 
for different surgery site, further study should be followed 
in future study.
We generated a prognostic model for TTF and OS 
for metachronous mRCC by dividing mRCC into low, 
intermediate, and high-risk groups. In both risk group 
classifications, sarcomatoid features and time to metastasis 
<1.5 years were negative prognostic factors, whereas a 
single metastasis site was a positive prognostic factor. In 
clinical practice, these three factors should be carefully 
reviewed for each patient, and secondary modalities 
should be recommended along with the primary treatment.
Our model demonstrated statistically significant 
discrimination ability as a survival model compared to 
the IMDC and MSKCC models (Supplementary Figure 
2). Because our model is specific to metachronous 
mRCC, we believe our model merits consideration for the 
application to patients with metachronous mRCC, which is 
correlated with relatively longer OS, compared to patients 
with synchronous mRCC, which is associated with more 
aggressive characteristics.
An mTOR inhibitor is one of the standard treatments 
for mRCC patients who fail initial TKI therapy [26, 27]. 
However, no prior studies have addressed prognostic 
factors for metachronous mRCC patients who received 
TKI treatment followed by an mTOR inhibitor. In this 
study, sarcomatoid features appeared the most powerful 
prognostic factor, exhibiting a clinical impact throughout 
the treatment period and a high HR. As previously 
demonstrated for synchronous mRCC, initial metastasis 
to bone was a predictor of poor outcome [28]. However, 
we should be very careful in interpreting and drawing 
meaningful conclusion out of this result, for the group size 
is small. There were 2 patients (6.3%) with sarcomatoid 
feature, and 4 patients (12.5%) with first metastasis to 
bone. For the sarcomatoid feature, each patient’s OS was 
3.5 month and 5.2 months, while the median OS of non-
sarcomatoid feature was 13.3 months [6.5, 23.8]. For the 
bone metastasis group, median OS was 3.6 months, while 
non-bone metastasis group showed median OS of 14.0 
months [6.65, 24.3].
The limitations of our study include its retrospective 
nature and the relatively small number of patients. As well, 
there was no standardization of preoperative imaging or 
postoperative surveillance. However, at present no clear 
standardization approach has been established to guide 
such endeavors. And as pre-existing model of IMDC and 
MSKCC is validated in all tumor histological subtypes, 
we also included all the subtypes and validated our 
model overall. However for the distinct characteristics of 
each subtype, further study is needed for the additional 
validation with the sufficient number of patients. Finally, 
no standardization existed regarding the performance 
or extent of a lymph node dissection, which might have 
caused the actual incidence of patients with pN+ disease 
to be underestimated. Nonetheless, we believe our results 
are sufficient to suggest a trend as well as the feasibility of 
developing a specific prognostic model of targeted agents 
for metachronous mRCC.
In this era of targeted therapies, the initial tumor size 
and T stage did not affect TTF and OS in metachronous 
mRCC once nephrectomy was performed and residual 
tumor was absent (R0). Thus, our results indicate that 
the prognosis prediction models should not be applied 
to patients with metachronous mRCC that has developed 
from synchronous mRCC. Metastasectomy could prolong 
the survival time of metachronous mRCC patients. 
Those who cannot undergo metastasectomy who develop 
multiple metastasis in a relatively short time, have higher 
corrected calcium levels, and sarcomatoid features 
identified pathologically are more likely to benefit less 
from targeted agents regarding survival outcome. In 
addition, our results indicate that patients who have 
tumors with sarcomatoid features and bone metastasis 
are more likely to achieve fewer survival benefits from 
mTOR inhibitor therapy. Accordingly, new agents under 
development or in clinical trials, including novel VEGF 
inhibitors, immune checkpoint inhibitors, viral vaccines, 
or combination therapies, could be more beneficial to 
these high-risk patients.
MATERIALS AND METHODS
Good clinical practice protocols
The study was performed in accordance with 
applicable laws and regulations, good clinical practices, 
and ethical principles as described in the Declaration of 
Helsinki, and was approved by the Institutional Review 
Board.
Patients
We retrospectively reviewed the medical charts 
of metachronous mRCC patients, defined as patients 
diagnosed with metastatic disease >3 months after 
the initial nephrectomy [29] with tumor relapse in the 
retroperitoneal space, lymph nodes, or other organs, treated 
at our institute between January 2005 and December 2015. 
Tumor relapse in the retroperitoneal space was defined as 
local recurrence, or recurrence within the retroperitoneal 
lymph nodes, the adrenal gland, or Gerota’s fascia. None 
of the patients received neoadjuvant or adjuvant treatment. 
All patients included in this study were surgically treated 
with radical nephrectomy or partial nephrectomy without 
evidence of residual tumor (R0). For the preoperative 
imaging study, we performed chest radiography and 
abdominopelvic computed tomography scans for all 
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patients, as well as bone scans or brain imaging if there 
were any symptoms or clinical indications.
Patients with synchronous metastatic disease 
at presentation or diagnosis of metastatic disease <3 
months after initial nephrectomy were excluded from 
the study, as well as patients who had received immune-
based therapy as an initial systemic treatment, had 
secondary malignancies, underwent discontinuation of 
targeted agents due to toxicity with or without a doctor’s 
permission, and patients with a T4 pathological stage 
due to the potential for microscopic residual tumor 
after resection. Time to metastasis was defined as the 
time period from initial nephrectomy to the date of 
metachronous metastasis. The independent time variable 
was 1.5 years from nephrectomy because it was close to 
the inflection point of the receiver operating characteristic 
curve for both TTF and OS in this study (data not shown).
Primary and secondary outcome measures
The primary outcome measures were TTF and OS, 
which were defined as the time between commencement 
of first-line targeted therapy and the date of progression 
and the time from the occurrence of disease metastasis to 
the date of death, respectively.
The secondary aim was to characterize treatment 
response to the targeted therapy agents. Targeted therapy 
treatment response was assessed nine months after 
commencement of targeted therapy because this was the 
median duration of initial targeted therapy in our study. 
Patients who survived and exhibited stable disease status 
following the first-line targeted therapy for ≥9 months 
were considered good responders, whereas those who were 
stable for <9 months were considered poor responders. 
Patients in complete remission before 9 months were 
categorized as good responders according to the Response 
Evaluation Criteria in Solid Tumors (RECIST v.1.1) [30].
Prognostic factors and OS were also analyzed in 
patients who received secondary mechanistic target of 
rapamycin (mTOR) inhibitor treatment following the 
administration of first-line tyrosine kinase inhibitors 
(TKI).
Statistical analysis
Independent analyses were carried out to identify 
prognostic factors for investigator-assessed OS and TTF. 
Prognostic variables were based on a previously reported 
general review of pretreatment features [1, 13, 14]. Factors 
in the univariate analyses were assessed using the log-rank 
test. Statistically significant factors were then included 
in the multivariate Cox proportional hazard regression 
analysis to assess the influence of clinical and pathological 
parameters. Binary logistic regression analysis was 
performed to investigate the clinical factors that predicted 
the TKI response. The Harrell’s C-statistic was used to 
evaluate the performance of our model compared with the 
two previous prediction models (IMDC and MSKCC) and 
95% confidence intervals (CI) of the resulting C-indexes 
were calculated by bootstrapping. One thousand bootstrap 
samples, which were generated by sampling the entire 
dataset of patients with replacement, were evaluated 
and 2-tailed 95% CIs were calculated. The 95% CIs 
of the pairwise differences between the C-indexes of 
the prognostic models were estimated using a similar 
approach. The area under the curve (AUC) was calculated 
by integrating over time to compare the performance 
trends or our model across survival time. The receiver-
operating characteristic (ROC) curve was also used to 
analyze the performance of our risk model using the death 
event as the dependent variable. All statistical analyses 
were conducted using the “R” statistical software version 
2.15.2.
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